LifeSci Acquisition: Jumps on cancer drug developer Vincera SPAC deal

Vincerx Pharma

29/09/2020 16:22

** Shares of blank check company  LSAC.O  jump ~13% to a
record high of $11.70 
    ** Co to take biopharma firm Vincera Pharma public through a
reverse merger; combined co to be listed on Nasdaq under the
symbol "VINC"  urn:newsml:reuters.com:*:nGNX2q9Z6d
    ** More than 600,000 shares traded, vs more than 160 times
LSAC's 50 daily moving average volume; stock's busiest ever day 
    ** The combined company is expected to have about $60 mln in
cash at deal close; deal due to be completed in Q4 
    ** LSAC raised $60 mln in its initial public offering in
March; LSAC had priced its IPO at $10 per unit  urn:newsml:reuters.com:*:nGNX9rm7Ty

 (Reporting by C Nivedita in Bengaluru)
 ((C.Nivedita@thomsonreuters.com;))